How Conditional FDA Approval of Credelio Quattro-CA1 Could Impact Elanco Animal Health (ELAN) Investors

Elanco Animal Health recently received conditional FDA approval for Credelio Quattro-CA1, the first companion animal treatment targeting New World screwworm infestations in dogs, reinforcing its ...

Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World ...

Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) for Credelio Quattro™-CA1 (lotilaner, moxidectin, ...
Nasdaq

Jaguar Health Completes Filing of New Animal Drug Application for Conditional Approval of Canalevia-CA1 (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs, Clearing ...

Canalevia™-CA1 is the first and only oral plant-based prescription drug candidate for CID in dogsJaguar kicks off educational awareness contest in honor of International Jaguar Day; Click here to ...
eFeedLink

US FDA approves MSD Animal Health's EXZOLT™ CATTLE-CA1 for treatment of New World screwworm

MSD Animal Health, a division of Merck & Co., Inc., on December 4 announced the US Food and Drug Administration (FDA) has ...

Elanco Animal Health: Elanco's Credelio Quattro-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment ...

Conditional Approval Marks Elanco's Third New World Screwworm Treatment Option for Companion Animals, Providing Multiple Treatment Solutions Prior to Fly Being Detected in the U.S. FDA's ...